The cell therapy developer, which raised nearly $500 million in 2023 on the promise of its CAR-T work, has floundered since a ...

Capricor Therapeutics has completed its US marketing application for deramiocel, a cell therapy the US biotech hopes will become the first approved treatment for cardiomyopathy associated with ...

Jasper Therapeutics faced a wave of downgrades Monday after disclosing that a compromised drug product lot disrupted results ...

This week brings our annual midsummer reality check with the full moon in Capricorn on the 10th. But, as is the case for much ...

Capricor Therapeutics stock plunges after key FDA officials placed on leave Investing.com -- Capricor Therapeutics Inc (NASDAQ:CAPR) stock tumbled 20.4% following news that two top FDA officials ...

Capricor Therapeutics' bid to find a partner for its Duchenne muscular dystrophy (DMD) cell therapy CAP-1002 could get a boost after final phase 2 data showed a strong effect on disease ...

Lynozyfic is one of two bispecific antibodies Regeneron hopes will lift its oncology business. Meanwhile, IGM is the latest struggling biotech to agree to a buyout deal from Concentra.

Get the cash flow statement for Capricor Therapeutics, Inc. (CAPR). Up to 10 years of financial statements. Quarterly or annual. View as % YoY growth or as % of revenue.

Shares of Zynex Inc. (NASDAQ:ZYXI) reached a 52-week high of $11.89 on Oct 3, closing the session marginally lower at $11.80.In... On Sep 25, we issued an updated research report on Align ...

Discover real-time Capricor Therapeutics, Inc. Common Stock (CAPR) stock prices, quotes, historical data, news, and Insights for informed trading and investment decisions. Stay ahead with Nasdaq.